$319.02
-9.71(-2.95%)
Mkt Cap $42.3B
$224.32
$491.22
52-Week Range
At a Glance
AI-generatedAlnylam Pharmaceuticals, Inc.
Revenue breakdown: Amvuttra (28.3%), Product (21.6%), TTR (17%).
8-K
Alnylam Pharmaceuticals reported fourth quarter and full year 2025 financial results, achieving global net product revenues of $995 million for Q4 and $2,987 million for the full year, representing 121% and 81% growth compared to 2024, respectively, and attaining GAAP and non-GAAP profitability for the full year. The company also launched its 'Alnylam 2030' strategy and provided 2026 financial guidance.$42.3B
Market Cap
$3.7B
Revenue
$315M
Net Income
Employees2,230
Fundamentals
How The Business Makes Money
Revenue by Segment
Amvuttra28.3%($7.7B)
Product21.6%($5.9B)
TTR17%($4.6B)
Collaborations6.1%($1.7B)
GIVLAARI5.8%($1.6B)
ONPATTRO5.7%($1.6B)
Rare4.6%($1.3B)
OXLUMO3.4%($937M)
License Obligation2.5%($675M)
Royalty1.1%($306M)
License1.1%($300M)
C5Monotherapy Obligation0.7%($192M)
Research Services Obligation0.6%($159M)
Development Services Obligation0.6%($159M)
Other License Programs0.4%($111M)
C5License Obligation0.2%($60M)
Product And Service Other0.1%($18M)
C5Co Co Obligation0%($8M)
Regeneron Technology Transfer Obligation0%($2M)
Revenue by Geography
US62.8%($3.7B)
Europe26.7%($1.6B)
Non US Or Europe10.5%($617M)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001178670
ISINUS02043Q1076
CUSIP02043Q107
Phone617 551 8200
Address675 West Kendall Street, Cambridge, MA, 02142, US
SEC EDGAR